Regeneron Pharmaceuticals ... but they eventually moved into the study of a blood vessel inhibitor known as a VEGF-trap. Their first blockbuster drug was drawn from the compound aflibercept ...

Regeneron has bought Oxular ... due to enrol 18 patients in the US who have been previously treated with anti-VEGF therapy like Eylea to one of two dose levels of OXU-001. Part B will recruit ...

Amgen had argued that the “VEGF antagonist” and “buffer” limitations are separate components, whereas Regeneron asserted that a “VEGF antagonist” can also satisfy the claimed “buffer ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Arcalyst is a first-in-class drug designed using Regeneron's 'Trap' technology. The drug is a fusion protein comprising the human interleukin (IL)-1 type 1 receptor (extracellular domain and ...

By reimbursing credit card fees, Regeneron subsidized the treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments. On this news, the price of Regeneron shares ...

By reimbursing credit card fees, Regeneron subsidized the treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments. On this news, the price of Regeneron shares ...